A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
A dose-escalating phase 1-2 study evaluating the safety and tolerability of istaroxime and its specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.